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Abstract
Background: The incidence of hepatocellular carcinoma with nonalcoholic steatohepatitis is increasing, and its
clinicopathological features are well established. Several animal models of nonalcoholic steatohepatitis have been
developed to facilitate its study; however, few fully recapitulate all its clinical features, which include insulin
resistance, inflammation, fibrosis, and carcinogenesis. Moreover, these models require a relatively long time to
produce hepatocellular carcinoma reliably. The aim of this study was to develop a mouse model of hepatocellular
carcinoma with nonalcoholic steatohepatitis that develops quickly and reflects all clinically relevant features.
Methods: Three-week-old C57BL/6J male mice were fed either a standard diet (MF) or a choline-deficient, high-fat
diet (HFCD). The mice in the MF + diethylnitrosamine (DEN) and HFCD + DEN groups received a one-time
intraperitoneal injection of DEN at the start of the respective feeding protocols.
Results: The mice in the HFCD and HFCD + DEN groups developed obesity early in the experiment and insulin
resistance after 12 weeks. Triglyceride levels peaked at 8 weeks for all four groups and decreased thereafter. Alanine
aminotransferase levels increased every 4 weeks, with the HFCD and HFCD + DEN groups showing remarkably high
levels; the HFCD + DEN group presented the highest incidence of nonalcoholic steatohepatitis. The levels of fibrosis
and steatosis varied, but they tended to increase every 4 weeks in the HFCD and HFCD + DEN groups. Computed
tomography scans indicated that all the HFCD + DEN mice developed hepatic tumors from 20 weeks, some of
which were glutamine synthetase-positive.
Conclusions: The nonalcoholic steatohepatitis-hepatocellular carcinoma model we describe here is simple to
establish, results in rapid tumor formation, and recapitulates most of the key features of nonalcoholic
steatohepatitis. It could therefore facilitate further studies of the development, oncogenic potential, diagnosis, and
treatment of this condition.
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Background
Worldwide, hepatocellular carcinoma (HCC) is the fifth-
most common cancer in men and seventh-most com-
mon in women, and its incidence has continuously in-
creased in recent years [1]. The major risk factors for
HCC are infection with hepatitis B and C viruses; how-
ever, the incidence of viral-related HCC has decreased
owing to improvements in the management and treat-
ment of viral infections. Meanwhile, the frequency of
non-viral HCC—related to alcohol consumption and
other factors—has gradually increased. Nonalcoholic
fatty liver disease (NAFLD), which is a hepatic manifest-
ation of metabolic syndrome, is one of the most com-
mon causes of chronic liver disease and liver cirrhosis in
the world [2, 3]. NAFLD ranges from simple steatosis to
nonalcoholic steatohepatitis (NASH) associated with in-
flammation, fibrosis, and carcinogenesis [4]. In accord-
ance with multiple-hit theory, metabolic syndrome,
genetic factors, oxidative stress, inflammatory cytokines,
endotoxins, and insulin resistance have been shown to
be involved in NASH development and the progression
of NASH-HCC [5]. A number of studies describing the
natural history of NASH have found liver failure and
HCC to be the major causes of death [6–12].
Various genetic and dietary NASH animal models
exist. For example, PTEN knockout mice undergo car-
cinogenesis, and exhibit steatohepatitis, but not obesity,
dyslipidemia, or insulin resistance [13]. ob/ob mice are
diabetic owing to a defect in the leptin gene and genetic-
ally obese; db/db mice have a defective leptin receptor
gene [14, 15]. Dietary models include a high-fat diet
(HFD) model [16], a high-fat, choline-deficient diet
model (HFCD) [17, 18], a methionine- and choline-
deficient diet (MCD) model [19, 20]. These models re-
quire a relatively long period—usually about 1 year—to
produce HCC [17]. A 16-week NASH-HCC mouse
model based on an HFD combined with low-dose strep-
tozotocin (STZ) has been reported [21]; however, those
mice were not insulin resistant, because they exhibited a
lack of insulin secretion. The liver carcinogenicity of
diethylnitrosamine (DEN) has been reported [22–24],
and DEN has been added to the rat NASH-HCC model
in combination with an HFD [25–27]. A few models ex-
hibit all the associated clinical features of NASH-HCC,
such as insulin resistance, inflammation, fibrosis, and
carcinogenesis, such as a high-fat and fructose diet
model [28]. Recent genetic and dietary NASH-HCC
models have included MUP-uPA transgenic mice with
HFD [29] and melanocortin 4 receptor (MC4R) knock-
out mice with HFD [30].
Since there is no effective treatment or chemopre-
vention for HCC related to NASH, a mouse model
with the same clinical features as human NASH is
needed. In this study, by feeding C57BL/6 mice an
HFCD combined with DEN exposure, we developed a
novel experimental NASH-HCC mouse model that
exhibits all the relevant clinical features by 20 weeks,




Three-week-old male C57Bl/6J mice were purchased
from Oriental Yeast (Tokyo, Japan), housed in a
temperature-, humidity-, and ventilation-controlled viv-
arium, and kept on a 12-h light/dark cycle under specific
pathogen-free conditions. For the DEN intraperitoneal
(i.p.) experiment, the mice were randomly divided into
two groups: the standard diet (MF) group, which was
fed an MF (11.4 % fat, 25.7 % protein, 62.9 % carbohy-
drate, total calories 359 kcal/100 g; purchased from
Oriental Yeast); and the HFCD group, which was fed an
HFCD (58.0 % fat, 16.4 % protein, 25.5 % carbohydrate,
total calories 556 kcal/100 g; purchased from Oriental
Yeast) [17]. The two groups were further divided into
two subgroups, one of which was treated with DEN. The
MF +DEN and HFCD +DEN subgroups received a one-
time i.p. injection of 25 mg/kg DEN at the start of the
respective feeding protocols. Food and water were given
ad libitum. Five mice from each group were sacrificed
every 4 weeks, and their body weights and liver weights
measured. An overview of the experimental protocol ap-
pears in Fig. 1.
All procedures for animal experimentation were in ac-
cordance with the Helsinki Declaration of 1975 and In-
stitutional Guidelines on Animal Experimentation at
Keio University. This study was approved by the Keio
University Institutional Animal Care and Use Committee
(Approval number: 08073).
Measurement of biological parameters
Serum levels of fasting blood sugar (FBS), alanine ami-
notransferase (ALT), and triglyceride (TG) were mea-
sured using a Fuji Dri-Chem 3500 analyzer (Fuji Film
Co. Ltd, Tokyo, Japan). Insulin levels were determined
using a mouse insulin enzyme-linked immunoassay kit
(Morinaga Institute of Biological Science, Inc. Yokohama,
Japan). The quantitative insulin sensitivity check index
was calculated as 1/log (fasting insulin) + log (fasting
glucose). Interleukin (IL)-6, tumor necrosis factor (TNF)-
alpha, leptin, adiponectin, and C-reactive protein (CRP)
levels were measured using Procarta Multiplex Immuno-
assays (Affymetrix eBioscience, San Diego, CA, USA).
Serum amyloid A (SAA) was determined using the
PHASE RANGE Mouse SAA ELISA kit (Tridelta Devel-
opment Ltd., Kildare, Ireland).
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Insulin tolerance test
To assess insulin resistance, we performed an insulin
tolerance test. Mice were injected with 1 U/kg of insulin
(Humulin R; Eli Lilly Japan, Kobe, Japan), and blood glu-
cose was measured using an Accu-Chek meter (Roche
Diagnostics Japan, Tokyo, Japan) every 20 min up to
120 min. The ratio was calculated using the pre-
injection value as a standard.
Histological analysis
Liver tissue was assessed grossly, and samples were fixed
in 10 % formaldehyde and processed for hematoxylin-
eosin staining. Variables were blindly scored by two
experienced hepatopathologists using a modified scoring
system adapted from the NAFLD activity score (NAS):
macrosteatosis (0–3); lobular inflammatory changes
(0–3); hepatocyte ballooning (0–2); and fibrosis scored
as portal and perivenular (stage 0–4).
Immunohistochemical detection of F4/80 (a macro-
phage marker) was performed as follows. Paraffin
sections were deparaffinized in xylene, hydrated in a gra-
dient of ethanol, and incubated with proteinase K for
10 min at room temperature for antigen retrieval. The
sections were then incubated with a primary rat anti-
mouse F4/80 antibody (T-2006; BMA Biomedicals,
Augst, Switzerland) overnight at 4 °C, followed by incu-
bation with Histofine Simple Stain mouse MAX-PO
(Rat) (Nichirei Bioscience, Tokyo, Japan) for 30 min.
Staining was detected using diaminobenzidine tetrahy-
drochloride. Three light microscopy images at 100
times magnification were taken of each slide to deter-
mine the ratio of F4/80-positive cells (macrophages) to
hepatocyte nuclei.
Immunostaining for glutamine synthetase (GS) was
performed by the Stelic Institute & Co., Inc. (Tokyo,
Japan). Sirius red staining was performed using Van
Gieson’s stain solution and Sirius red solution from
Muto Pure Chemicals Co., Ltd. (Tokyo, Japan). The
degree of liver fibrosis was assessed using Histoquest
(Tissue Gnostics, Vienna, Austria) using the three
Fig. 1 Overview of the experimental design, showing intraperitoneal diethylnitrosamine (DEN) administration. N, number; GA, general assessment;
CT, computed tomography scanning
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images of each slide described above. The caudate liver
lobes were embedded in Tissue-Tek OCT compound
(Sakura Finetechnical Co., Ltd., Tokyo, Japan) and snap-
frozen in liquid nitrogen. Frozen sections, 5 μm thick,
were fixed with 50 % ethanol for 5 min and stained with
Sudan III (Wako Pure Chemical Industries Ltd., Osaka,
Japan) in 55 % ethanol for 1.5 h at room temperature.
X-ray computed tomography
For the detection and characterization of tumor develop-
ment, the mice were imaged using the in vivo three-
dimensional micro X-ray computed tomography (CT)
system R-mCT2 (Rigaku, Tokyo, Japan). The X-ray tube
voltage, current, and field of view were 90 kV, 200 μA,
and 30 mm, respectively. ExiTron nano 6000 (Miltenyi
Biotec, Bergisch Gladbach, Germany) was injected into
the tail vein of the mice on the day before the CT scan
at a dose of 10 mL/kg. ExiTron nano 6000 is uptake by
Kupffer cells in liver, therefore, we defined the nodules
which were not enhanced by ExiTron nano 6000. Using
512 CT image of samples, largest diameter of node and
numbers were measured by Osirix software (OnDemand
software, Cybermed Inc., Bernex, Switzerland).
Comparison of HFCD + DEN and HFD32 + DEN
High Fat Diet 32 (HFD32) was obtained from CLEA
Japan, Inc. (Tokyo, Japan). This diet consists of 32.0 %
fat, 25.5 % protein, 29.4 % carbohydrate, and total calo-
ries of 507.6 kcal/100 g. Five 3-week-old male mice
were fed HFD32 and received a one-time i.p. injection
of 25 mg/kg DEN at the start of the feeding protocol.
After 4 weeks, liver tissue was taken and snap-frozen in
liquid nitrogen.
RNA was extracted from frozen liver tissue after
4 weeks of MF, HFCD + DEN, and HFD32 + DEN using
the RNeasy Mini Kit (Qiagen, Hilden, Germany).
Genome-wide mRNA expression levels were deter-
mined using the Superprint G3 Mouse GE microarray
kit 8 x 60 k Ver 2.0, which contains 27,122 genes
(G4858A#074809, Agilent Technologies, South Queen-
sferry, UK). All microarray data of the HFCD + DEN
mice and HFD32 + DEN mice were normalized with
data of the MF mice using GeneSpring GX Ver 13.1
software (Agilent Technologies); the threshold was set
at more than twofold changes. We analyzed the data by
means of Qiagen’s Ingenuity Pathway Analysis (IPA)
software Ver 1.0 (Qiagen, Hilden, Germany) for func-
tional analysis. Molecules from the dataset that
exceeded the twofold cutoff and were associated with
biological function or diseases in the Ingenuity Know-
ledge Base were considered for analysis. The right-
tailed Fisher’s exact test was used to calculate a p value
to determine the probability that each biological
function or disease assigned to that dataset was due to
chance alone.
Statistical analysis
The data are shown as the mean ± standard deviation
or number (%). The Mann–Whitney U test was used
for the analysis of body and liver weight and ALT,
TG, and leptin levels. We performed all statistical
analyses using IBM SPSS Statistics 21 software (SPSS,
Inc., Chicago, IL, USA).
Results
Body weight, liver weight, and laboratory findings
To develop the NASH-HCC model, we used a combin-
ation of an HFCD and i.p. DEN administration. The
mice were divided into four groups: MF; HFCD; MF +
DEN; and HFCD +DEN. Animals in the MF +DEN and
HFCD +DEN groups received a single i.p. injection of
DEN at the start of the respective feeding protocols. At
24 weeks, the mean body weights of the MF, HFCD,
MF + DEN, and HFCD + DEN mice were 31.7 g, 54.5 g,
32.6 g, and 49.5 g (Fig. 2a), respectively; the mean liver
weights were 1.2 g, 4.0 g, 1.3 g, and 2.9 g (Fig. 2b), re-
spectively. Both body weight and liver weight were sig-
nificantly higher in the HFCD and HFCD +DEN
groups than in the MF and MF + DEN groups.
Plasma ALT levels increased every 4 weeks, with the
HFCD and HFCD +DEN groups showing remarkably
high levels (Fig. 2c). Plasma TG levels peaked at 8 weeks
for all four groups and decreased thereafter (Fig. 2d).
There were significant differences in TG levels between
the MF and HFCD +DEN groups at 16 and 20 weeks.
Plasma leptin levels increased from 20 weeks in the
HFCD and HFCD +DEN groups (Fig. 2e). Plasma adipo-
nectin levels decreased from 20 weeks in the HFCD and
HFCD +DEN groups (Fig. 2f ).
The levels of other biomarkers, such as FBS, CRP, IL-
6, and TNF-alpha, are shown in Table 1. CRP levels in-
creased from 20 weeks in the HFCD and HFCD +DEN
groups, though there was no significant difference. How-
ever, compared with the MF group, serum levels of
TNF-alpha were higher in the HFCD group at 4 and
8 weeks and in the HFCD +DEN group at 8 weeks.
Serum levels of IL-6 tended to be higher in the HFCD
and HFCD +DEN groups; however, at 16 weeks, only
the HFCD group exhibited significantly different levels
compared with the MF group.
Insulin resistance
Insulin resistance was calculated using the quantitative
insulin sensitivity check index. All mice in the HFCD
and HFCD +DEN groups had developed insulin resist-
ance at 12 weeks, whereas animals in the MF and MF +
DEN groups had developed insulin resistance at 24 weeks
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(Table 2). To confirm the development of insulin resist-
ance, we performed an insulin tolerance test. There was
a significant difference in insulin resistance between the
MF and HFCD +DEN groups at 80 and 100 min. There
was also a significant difference in insulin resistance
between the MF and HFCD groups at 80, 100, and
120 min (Fig. 3).
Histological findings of non-tumor tissue
Liver specimens were evaluated using hematoxylin-eosin
staining. At 12 weeks, mice in the HFCD and HFCD +
DEN groups evidenced fat accumulation, lobular in-
flammation, and hepatocyte ballooning, which are char-
acteristic of NASH. These changes were more evident
in specimens from the HFCD + DEN group than in
those from the HFCD group (Fig. 4a). We observed no
apparent pathological findings, including fatty degener-
ation or necroinflammatory changes in hepatocytes in
the hematoxylin–eosin-stained tissue of MF or MF +
DEN mice. Sudan III staining revealed remarkable
macrovesicular fat accumulation in both the HFCD and
HFCD + DEN groups at 12 weeks; microvesicular fat
accumulation was evident in the MF group—and to a
lesser extent in the MF + DEN group (Fig. 4b). Lipogra-
nuloma (Fig. 4c), Mallory-Denk bodies (Fig. 4d), and
hepatocyte ballooning (Fig. 4e), which are characteristic
of NASH, were observed in the HFCD + DEN mice
from 16 weeks after feeding.
NAS is an established scoring system for assessing the
severity of NASH. In the NAS system, a score of 3–5
represents possible or borderline NASH; a score greater
than 5 indicates definite NASH. The NAS was possible
or borderline from 16 weeks and definite from 20 weeks
in the HFCD mice; it was possible or borderline from
12 weeks and definite from 16 weeks in the HFCD +
DEN group (Table 3).
To evaluate inflammation, we undertook immunohisto-







Fig. 2 Body and liver weights and laboratory findings: a body weight; b liver weight; c plasma alanine aminotransferase (ALT); d plasma triglycerides
(TG); e plasma leptin; and f adiponectin. The data are shown as the mean + standard deviation. * p < 0.05 indicates a significant difference between
the standard diet (MF) group and the other groups for each month. HFCD, high-fat choline-deficient diet; DEN, diethylnitrosamine
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and SAA measurement. Representative images of macro-
phages in the perivenular zone at 4 weeks in the MF and
HFCD+DEN mice are presented in Fig. 5a, b. The ratio
of F4/80-positive cells (macrophages) to hepatocyte nuclei
was higher in the HFCD and HFCD +DEN groups than
in the other two groups from 4 weeks (Fig. 5c). SAA was
significantly higher after 20 weeks in the HFCD+DEN
mice and at 24 weeks in the HFCD mice (Fig. 5d). Fibrosis
was more conspicuous in the HFCD and HFCD + DEN
mice than in the other two groups (Fig. 5e). The area of
fibrosis increased dramatically from 12 weeks in the
HFCD + DEN mice and from 16 weeks in the HFCD
group (Fig. 5f ).
CT scans and immunohistochemistry of hepatic tumors
To evaluate tumor development, we performed a CT
scan every 4 weeks from week 12. The largest liver mass
had a maximum diameter of 13 mm at 24 weeks in the
HFCD + DEN group (Fig. 6a, b). Small nodules were typ-
ically seen in the liver macroscopically and by CT scan
at 24 weeks (Fig. 6c–e). Positive findings were evident in
20 % and 100 % of the HFCD +DEN mice at 16 weeks
and 20 weeks, respectively. Only one mouse had positive
findings in the HFCD group at 20 weeks and one mouse
in the MF + DEN group at 24 weeks. In the HFCD +
DEN group, there were on average eight tumors at
24 weeks, with an average size of 2.9 mm (Table 4). To
confirm malignancy, we immunostained the tumors to
detect GS. GS-positive HCC was found in some speci-
mens (Fig. 6f, g), although not all tumors were stained.
Comparison of HFCD + DEN and HFD32 + DEN
To determine why HFCD +DEN promoted cancer de-
velopment, we performed RNA microarray analysis. For
this, we used HFD32, which is a widely employed high-
fat diet. Principal component analysis provides a way of
identifying predominant gene expression patterns.
Surprisingly, the general expression of HFCD +DEN was
closer to MF than to HFD32 + DEN (Fig. 7a). Clustering
analysis and gene ontology analysis indicated that
Table 1 Summary of laboratory findings for FBS, CRP, IL-6, TNF-alpha, and adiponectin levels
Week MF HFCD MF + DEN HFCD + DEN
FBS (mg/dl) 4 211.3 ± 41.7 297.5 ± 24.6 191.0 ± 11.2 282.3 ± 26.5
8 149.6 ± 30.9 174.2 ± 32.9 177.0 ± 64.9 167.6 ± 31.3
12 167.6 ± 41.6 241.6 ± 32.4 152.0 ± 24.2 273.4 ± 31.5
16 109.8 ± 11.4 245.0 ± 46.4 112.8 ± 8.7 189.8 ± 52.5
20 188.4 ± 14.6 263.2 ± 36.0 172.0 ± 36.7 242.0 ± 14.4
24 165.2 ± 23.9 265.2 ± 6.5 205.3 ± 32.5 249.4 ± 24.2
CRP (ng/ml) 4 4552.6 ± 2533.3 3756.8 ± 1366.4 4284.9 ± 2261.0 4915.4 ± 1697.0
8 5803.1 ± 1368.7 13324.9 ± 7100.6 5837.7 ± 2422.0 6568.3 ± 3827.0
12 2412.0 ± 211.8 2505.3 ± 517.7 2465.9 ± 170.5 2427.1 ± 337.3
16 2080.4 ± 756.5 3065.7 ± 1047.4 2801.3 ± 457.0 3002.1 ± 599.5
20 2125.1 ± 306.9 3170.3 ± 711.8 2185.4 ± 256.3 3293.4 ± 416.6
24 2227.6 ± 613.8 3143.3 ± 393.3 2044.0 ± 349.9 3686,7 ± 481.2
IL-6 (pg/ml) 4 0.2 ± 0.3 1.3 ± 1.5 0.3 ± 0.5 0.9 ± 1.3
8 0.5 ± 0.5 1.8 ± 1.5 0.6 ± 0.7 0.9 ± 1.2
12 0.8 ± 0.5 1.1 ± 0.7 1.1 ± 0.8 2.0 ± 1.5
16 1.3 ± 0.6 2.9 ± 1.2 1.2 ± 0.8 0.9 ± 0.2
20 1.6 ± 1.2 1.3 ± 0.8 1.4 ± 0.9 1.6 ± 0.9
24 2.1 ± 1.3 4.2 ± 1.8 2.2 ± 4.5 1.6 ± 0.3
TNF-alpha (pg/ml) 4 N.D. 20.7 ± 28.9 N.D. 6.2 ± 12.0
8 1.8 ± 3.9 270.9 ± 297.5 5.0 ± 7.1 134.6 ± 153.7
12 2.2 ± 2.8 0.4 ± 0.9 0.9 ± 2.0 1.9 ± 3.1
16 0.1 ± 0.1 3.4 ± 4.8 0.1 ± 0.3 N.D.
20 1.2 ± 1.6 2.0 ± 2.2 1.4 ± 1.4 1.4 ± 1.3
24 3.8 ± 6.4 5.8 ± 3.0 3.5 ± 5.2 0.5 ± 1.2
The data are shown as the mean ± standard deviation. Each group contained five mice. FBS fasting blood sugar, CRP C-reactive protein, IL interleukin, TNF-alpha
tumor necrosis factor-alpha
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probably as a result of hepatitis, HFCD + DEN and
HFD32 commonly changed the expression gene related
to defense response and immune response. Functional
analysis extracted 13 genes from HFCD +DEN and 163
from HFD32 + DEN related to HCC: HFCD +DEN and
HFD32 + DEN were found to have six genes in common.
As seen in the heat map in Fig. 7b and Additional file 1,
expression of Histone cluster 1, H3c (Hist1h3c), histone
cluster 1, H3g (Hist1h3g), Mitochondrial transcription
termination factor 2 (Mterf2), ArfGAP with SH3 do-
main, ankyrin repeat and PH domain 2 (Asap2), and
Hair growth associated (Hr) showed an increase in both
the HFCD+DEN and HFD32 +DEN groups. Expression
of Retinoblastoma binding protein 6 (Rbbp6) in HFCD+
DEN presented a slight decrease, though it was a large de-
crease in HFD32 +DEN.
Discussion
It has been reported that the development and progres-
sion of NASH-HCC follows a multiple-hit pathway,
which includes metabolic syndrome, genetic factors,
oxidative stress, inflammatory cytokine release, endo-
toxins, and insulin resistance [5]. Previous NASH
models have combined two or more of these hits by
using a special diet with a chemical agent [21, 27] or
specific genetic changes [14, 20]. However, these de-
mand relatively long periods before the onset of HCC.
NASH models based only on an HFCD require consid-
erably longer periods—usually more than 1 year—to
reliably produce carcinoma [17]. By combining an
HFCD with a chemical agent, DEN, our model resulted in
Table 2 Insulin resistance calculated using the quantitative
insulin sensitivity check index
4 W 8 W 12 W 16 W 20 W 24 W
MF N.D. 0.227 0.139 N.D. N.D. 0.413
0.064 N.D. 0.348 N.D. 0.445 0.12
N.D. 0.381 0.193 N.D. N.D. 0.249
N.D. N.D. 0.416 0.315 N.D. 0.777
N.D. N.D. 0.672 N.D. N.D. 0.083
HFCD N.D. 0.22 0.089 0.058 0.026 0.045
0.2002 0.206 0.047 0.034 0.026 0.025
0.3954 0.168 0.067 0.034 0.057 0.025
0.0705 N.D. 0.081 0.027 0.034 0.018
0.1384 N.D. 0.046 0.079 0.037 0.030
MF + DEN 1.047 N.D. 0.579 N.D. N.D. 0.2916
N.D. N.D. N.D. N.D. N.D. 0.116
N.D. 0.916 N.D. 0.642 N.D. 0.131
N.D. 0.916 N.D. N.D. N.D. 0.153
N.D. 0.159 N.D. 9.101 0.245 N.D.
HFCD + DEN 1.047 0.0808 0.016 0.072 0.033 0.026
N.D. 0.1167 0.031 0.054 0.063 0.020
0.1026 0.377 0.030 0.025 0.069 0.034
0.0826 0.315 0.048 0.314 0.201 0.031
0.172 0.173 0.036 0.022 0.055 0.037
The quantitative insulin sensitivity check index = 1/log (fasting insulin) + log
(fasting glucose). A value < 0.3 indicates insulin resistance; values from 0.348 to
0.430 are normal, and values ≥ 3.0 indicate high insulin sensitivity (type 1
diabetes mellitus). Index values < 0.3 (insulin resistance) are in bold. Each group
contained five mice. W weeks, MF standard diet, HFCD high-fat choline-deficient
diet, DEN diethylnitrosamine, N.D not determined
Fig. 3 Insulin tolerance test at 12 weeks. The data appear as the mean + standard deviation. * p < 0.05 indicates a significant difference between
the standard diet (MF) group and the high-fat, choline-deficient diet (HFCD) + diethylnitrosamine (DEN) group. ** p < 0.05 indicates a significant
difference between the MF and HFCD groups
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carcinoma within 20 weeks. DEN increases oxidative
stress [31], which is one of the most important factors in
the development and progression of NASH since it stimu-
lates Kupffer cells [32]. Mice in the HFCD +DEN group
showed elevated SAA levels, a higher NAS, and earlier fi-
brosis than those in the HFCD group. We also demon-
strated that our NASH mouse model—based on an HFCD
combined with i.p. injection of DEN—stimulated insulin
resistance, fibrosis, and HCC within 20 weeks (Fig. 8).
The MCD model is one of the best-known NASH
animal models [19, 20]. Choline deficiency causes
Cyp2E1 upregulation with increased reactive oxygen
species formation, lipid peroxidation, and mitochon-
drial dysfunction [27]; methionine deficiency exacer-
bates hepatic injury associated with oxidative and
endoplasmic reticulum stress [33]. Although MCD
mice develop steatohepatitis, fibrosis, and carcinogen-
esis, both body weight and insulin resistance tend to
decrease because of reduced food intake and in-
creased basal metabolism. The MCD model thus re-
flects a different pathophysiology than human NASH
with respect to metabolic syndrome.
Few reported NASH-HCC models have fully incorpo-
rated all the clinical changes associated with that disease
[28–30]. In our HFCD +DEN model, tumor initiation is
basically dependent on a chemical carcinogen, which is
artificial compared with the above spontaneous HCC
Fig. 4 Representative images of stained liver sections: a 12 weeks with hematoxylin-eosin staining; b 12 weeks with Sudan staining; c–e 16 weeks in
HFCD +DEN mice with hematoxylin-eosin staining. The original magnification is × 200 (a–c) and × 400 (d). Lipogranuloma (c), a Mallory-Denk body (d),
and hepatocyte ballooning (e) are indicated by yellow arrowheads. MF, standard diet; HFCD, high-fat choline-deficient diet; DEN, diethylnitrosamine
Table 3 Nonalcoholic fatty liver disease activity score (NAS)
Week MF HFCD MF + DEN HFCD + DEN
NAS 4 0 0.6 ± 0.9 0.6 ± 0.6 1.3 ± 0.5
8 0 0.8 ± 0.8 0.4 ± 0.6 1.2 ± 1.6
12 0 2.6 ± 1.7 1 ± 0 3 ± 2.0
16 0.2 ± 0.5 4.6 ± 2.2 1 ± 0 5.2 ± 1.3
20 0 5.2 ± 0.5 1 ± 0 5.4 ± 0.6
24 0 6.2 ± 0.8 1 ± 0 5.6 ± 0.6
Each group contained five mice. MF standard diet, HFCD high-fat choline-
deficient diet, DEN diethylnitrosamine
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models. Thus, the HFCD + DEN model cannot assess
the initiation step of NASH-HCC. However, the time to
HCC development in our HFCD + DEN model is
20 weeks. This is the shortest among comparable mod-
els—the high-fat and fructose diet model, MUP-uPA
transgenic mice with HFD, and MC4R knockout mice
with HFD, which have 48, 32, and 48 weeks, respectively.
Therefore, the HFCD + DEN model may be appropriate
to assess how the NASH environment promotes HCC.
Our functional analysis extracted 13 genes from
HFCD +DEN and 163 from HFD32 + DEN related to
HCC. Expression of Rbbp6 in HFCD+DEN and HFD32 +
DEN decreased (Fig. 7b). Rbbp6 is known to interact with
MDM2, and it enhanced the affinity of MDM2 for p53,
which led to the ubiquitination and degradation of p53 and
repression of p53-dependent gene transcription. It would
be interesting to explore in detail the differences in the
cancer development mechanisms among those models.
One limitation with this analysis is that the samples
covered only a 4-week duration. We were thus unable to
observe the long-term effects of gene expression. Further




Fig. 5 Immunohistochemistry with F4/80 antibody (×200 original magnification) at 4 weeks: a standard diet (MF) group; b high-fat, choline-
deficient diet (HFCD) + diethylnitrosamine (DEN) group; c the ratio of F4/80-positive cells (macrophages) to hepatocyte nuclei; d serum amyloid A
(SAA) immunostaining; e representative images of liver sections stained with Sirius red at 24 weeks; and f proportion of fibrotic area measured
using Histoquest. The data are shown as the mean + standard deviation
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Fig. 6 Computed tomography scans and immunohistochemistry of hepatic tumors in the high-fat, choline-deficient (HFCD) + diethylnitrosamine
(DEN) group at 24 weeks: a, c computed tomography findings; b–e macroscopic views. The image in a is a section of the whole liver depicted in
b; the image in c is a section of the whole liver shown in d; and the image in panel e depicts the right and left medial lobes of the whole liver
in panel d. The lesions are indicated by yellow arrowheads. f Hematoxylin-eosin staining of the liver tumor. g Immunohistochemical staining for
glutamine synthetase
Table 4 Summary of computed tomography findings, rate of positive findings, tumor number, and tumor size from 12 to 24 weeks
Week MF HFCD MF + DEN HFCD + DEN
Mice with positive findings, n (%) 12 0 0 0 0
16 0 0 0 1/5 (20 %)
20 0 1/5 (20 %) 0 5/5 (100 %)
24 0 0 1/5 (20 %) 5/5 (100 %)
Tumor number 12 0 0 0 0
16 0 0 0 5
20 0 6 0 10.0 ± 5.4
24 0 0 1 8.8 ± 5.4
Tumor size (mm) 12
16 0.6 ± 0.4
20 0.8 ± 0.2 1.6 ± 0.8
24 2.2 2.9 ± 2.8
Data are shown as the mean ± standard deviation. Data in bold indicate a significant difference (p < 0.05) between the standard diet (MF) group and the other
groups for each month. HFCD high-fat choline-deficient diet, DEN diethylnitrosamine
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Insulin resistance is another essential feature of NASH,
which is a hepatic manifestation of metabolic syndrome
[34], and insulin resistance plays an important role in
exacerbation of NASH. A number of NASH models with
diabetes mellitus, such as the KK-Ay mouse on the MCD
diet and mice fed an HFD combined with STZ, have been
reported [20, 21]. The KK-Ay mouse is a genetically
engineered diabetes mellitus model with insulin resistance,
but it is unclear whether it exhibits carcinogenesis. STZ
destroys the insulin-producing beta cells of the pancreas;
therefore, mice receiving STZ develop type 1 diabetes
mellitus owing to a lack of insulin secretion rather than
through the de novo development of insulin resist-
ance. In our study, most mice exhibited insulin resist-
ance after 12 weeks (Table 2, Fig. 3).
Although a few mice in our model developed liver
cirrhosis, we believe this model will be beneficial for
studying NASH-HCC. Clinically, it is unclear whether
cirrhosis is a prerequisite for the development of HCC
in patients with NASH. Cirrhosis and advanced fibrosis
appear to be the predominant risk factors for HCC
development; however, 28 % of NASH-associated HCC
cases have less advanced forms of fibrosis (stage 1 or 2),
and fibrosis is more frequent in men [7].
Based on CT findings, all mice in the HFCD + DEN
group, but no animals in the HFCD group, had liver
tumors at 20 weeks (Table 4). Histologically, focal
nodular hyperplasia and dysplasia were also present.
Consistent with these findings, our immunohistochem-
istry results showed both GS-positive HCC (Fig. 6g)
and GS-negative tumors.
Leptin is a peptide hormone produced by adipocytes
and is involved in appetite control and energy expend-
iture [35]. Obese patients often have leptin resistance
and high serum levels of leptin, which exacerbate obesity
and hypertension owing to a sustained increase in sym-
pathetic nerve activity. Hyperleptinemia is also related to
hyper-responsiveness to low-dose endotoxin, which is
Fig. 7 Expression of MF, HFCD + DEN, and HFD32. a Principal component analysis of MF (brawn), HFCD + DEN (red), and HFD32 + DEN (blue). MF
group contained three mice. HFCD + DEN and HFD32 + DEN group contained five mice. b Heat map of HCC-related genes common to both
HFCD + DEN and HFD32 + DEN. DEN, diethylnitrosamine; standard diet (MF); HFCD, high-fat, choline-deficient diet; HFD32, high-fat diet
Fig. 8 Summary of the experimental model. DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis
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associated with NASH progression [36]. The mice in our
model developed hyperleptinemia (Fig. 2e) and hypoadi-
ponectinemia (Fig. 2f ) after 20 weeks. Park et al. have re-
ported that feeding HFD to DEN-treated mice promotes
HCC development through TNF and IL-6 expression
[37]. Serum levels of TNF-alpha were higher in the
HFCD and HFCD +DEN groups than in the MF group
at 4 and 8 weeks; however, this difference was not sig-
nificant owing to large individual differences within each
group (Table 1). Our findings appear to be consistent
with those of another report, which found the adipocyto-
kine level to be highest at 8 weeks and gradually de-
creased thereafter [21]. Although, the reason for this is
unknown, serum levels of TNF-alpha and IL-6 after
12 weeks were not particularly high compared with
those in the MF group.
Wolf et al. recently reported that long-term feeding an
HFCD diet to mice can induce HCC, which depends on
intrahepatic CD8+ T cells and NKT cells [38]. In our
microarray analysis results, many genes known to affect
the immune response exceeded the twofold cutoff.
A mouse model that bears the same clinical features
as human NASH-HCC can be used for research into the
treatment and chemoprevention of HCC resulting from
NASH. One advantage of a mouse model is that a
smaller drug amount is needed than with a rat model.
Mice also have shorter generation times than rats. They
are thus an efficient model for appropriate research by
drug therapies. The most important advantage of a
murine model is the anatomical and genetic similarity of
mice to humans.
Conclusion
The NASH-HCC model we describe here is simple to
establish, results in rapid tumor formation, and reca-
pitulates most of the key features of NASH. It could
therefore facilitate further studies into the develop-
ment, oncogenic potential, diagnosis, and treatment of
this condition.
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